• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Denmark·Healthcare·NOVO-B.CO
Held by 2 Gurus
Share

Novo Nordisk A/S Stocks

DKK 292Last Updated 08.09.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

DKK 206.32B

DKK 292
Key Takeaways

Risk factor

Low default risk

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Steven Cohen

Portfolio Weight (%)

0.2%

Change

+0.11%

Fund

Point72 Asset Management, L.P.

Kenneth Griffin

Portfolio Weight (%)

0.1%

Change

-0.01%

Fund

CITADEL ADVISORS LLC

Manager
Fund
Portfolio Weight (%)
Change
Steven CohenPoint72 Asset Management, L.P.0.2%+0.11%
Kenneth GriffinCITADEL ADVISORS LLC0.1%-0.01%

Latest news

27.08.2026 20:41

Deutsche Bank recommended selling Novo Nordisk shares after they fell 70% from their peak

17.08.2026 17:07

Motley Fool sees big risks and big upside in anti-obesity drugmakers Viking, Kailera

05.08.2026 23:41

Lilly raised its revenue forecast. This eased fears that the weight-loss boom is on the decline

05.08.2026 08:30

Weak sales of Wegovy overshadowed Novo's "clearly less-than-impressive" forecast revision

03.08.2026 11:43

SpaceX's Earnings Report, the Job Market, and Big Pharma: What Investors Can Expect This Week

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Novo Nordisk A/S, along with its affiliated companies, focuses on the discovery, production, and global sale of pharmaceutical goods. Its market presence extends across Europe, the Middle East, Africa, North America, and various Asian territories, including Mainland China, Hong Kong, and Taiwan. The company's activities are divided into two main categories: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division offers therapeutic solutions for conditions such as diabetes, obesity, cardiovascular health, and other developing medical areas. Meanwhile, the Rare Disease division provides treatments for unusual blood conditions, uncommon endocrine disorders, and hormone replacement therapies. Beyond its drug portfolio, Novo Nordisk also manufactures medical devices like insulin pens, growth hormone pens, and injection needles. Furthermore, it develops intelligent tools for diabetes management, including advanced smart insulin pens and the Dose Check application, designed to assist with insulin dosage guidance. The company holds a cooperative agreement with Aspen Pharmaceuticals for the manufacturing of insulin products. Novo Nordisk A/S was founded in 1923 and its corporate headquarters are located in Bagsvaerd, Denmark.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITDA, reasona

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of NOVO-B.CO is 300 and suggests 2.84% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommend

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

10.09.2026 00:40

RBC has warned of the risk of a 10% drop in U.S. stocks. What is putting pressure on them?

09.09.2026 23:58

The yield on 10-year Treasuries reached its highest level since 2023. What didn't sit well with the market?

09.09.2026 23:12

The Foldable iPhone and Price Increases: What Apple Announced at Its New Device Launch Event

09.09.2026 22:00

Zara's owner's profit fell short of expectations despite a strong start to the fall season

09.09.2026 21:37

UBS advised investors to set aside "clichéd stereotypes" about Europe and buy its stocks

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026